Adam J Olszewski
Overview
Explore the profile of Adam J Olszewski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
1729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Annunzio K, Grover N, Welkie R, Torka P, Watkins M, Anampa-Guzman A, et al.
Blood Adv
. 2023 Oct;
7(22):6839-6843.
PMID: 37792806
No abstract available.
12.
Pelcovits A, Ollila T, Olszewski A
Cancer Manag Res
. 2023 Sep;
15:989-998.
PMID: 37700809
Cutaneous T-Cell Lymphoma (CTCL) is a heterogenous disease that consists of distinct clinicopathologic entities and presentations requiring a unique and expert approach to management. The most common subtype is mycosis...
13.
Olszewski A, Phillips T, Hoffmann M, Armand P, Kim T, Yoon D, et al.
Blood Adv
. 2023 Aug;
7(20):6055-6065.
PMID: 37581593
Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 ×...
14.
Ollila T, Taher R, Moku P, Olszewski A
Blood Adv
. 2023 Jul;
7(18):5470-5479.
PMID: 37459209
Debate remains over the role of rituximab, a large molecule with reduced central nervous system (CNS) penetration, in therapy for primary CNS lymphoma (PCNSL). Since 2013, the National Cancer Database...
15.
Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh T, et al.
Blood Adv
. 2023 Jun;
7(17):5038-5046.
PMID: 37315169
Given the paucity of data surrounding the prognostic relevance of monoclonal paraprotein (M-protein) in marginal zone lymphoma (MZL), we sought to evaluate the impact of detecting M-protein at diagnosis on...
16.
Farooq F, Brandt J, Cardonick E, Polushkina E, Vose J, Ahmed S, et al.
Blood Adv
. 2023 Jun;
7(18):5480-5484.
PMID: 37259563
No abstract available.
17.
Bakow B, Phung Q, Rabinovich D, Olszewski A, Reagan J
J Thromb Thrombolysis
. 2023 May;
56(1):121-127.
PMID: 37219825
Antiphospholipid syndrome (APS) is an acquired hypercoagulable state necessitating long-term anticoagulation for secondary thrombosis prevention. Anticoagulation guidelines are predominantly based on data in high risk, triple positive patients, and favor...
18.
Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, et al.
Blood Adv
. 2023 May;
7(21):6381-6394.
PMID: 37171397
In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)-a rare category defined by high-grade morphologic features and...
19.
Epperla N, Welkie R, Torka P, Shouse G, Karmali R, Shea L, et al.
J Hematol Oncol
. 2023 May;
16(1):49.
PMID: 37158890
Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not...
20.
McKenna M, Epperla N, Ghobadi A, Liu J, Lazaryan A, Ibrahim U, et al.
Br J Haematol
. 2023 May;
202(2):248-255.
PMID: 37129856
The use of CD19 chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory solid organ transplantation (SOT)-related post-transplant lymphoproliferative disorder (PTLD) is not well studied. We conducted a multicentre, retrospective analysis...